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A 26-year-old male without any significant past medical history presented to the hospital with shortness of breath, cough, pleuritic
chest pain, and weight loss for the past 3 months. On chest CT, he was found to have extensive mediastinal and hilar lymphad-
enopathy andmultiple pulmonary nodules. On physical examination, a right groin mass was noted which had been slowly growing
for the past 2 years. Ultrasound of the groin showed complex solid mass with internal vascular channels. CT guided biopsy of the
mass showed desmoplastic small round cell tumour. His hospital course was complicated by hypoxic respiratory failure requiring
emergent intubation and ICU admission where he completed one cycle of vincristine, cyclophosphamide, and doxorubicin with
subsequent improvement, followed by extubation. His condition continued to improve after second cycle of chemotherapy and he
was ultimately discharged in a stable condition to continue outpatient chemotherapy after a 2-month inpatient stay.
1. Introduction
This case report describes our clinical experience in the
diagnosis and management of a rather uncommon malig-
nancy. Given the rarity of this condition, with less than 200
cases reported to date, every case experience such as ours
adds to the understanding of how varying clinical scenarios
can be successfully managed and what the responses looked
like. Additionally, a pool of such cases with information on
progression free survivals and response rates may then help
future investigators gain a better understanding of the efficacy
of such a regimen, safety signals of its components, and
management of any complications that clinicians may have
encountered. More importantly, we successfully investigated
and treated an intubated patient with chemotherapy to then
discharge him in an ambulatory condition. He maintains an
ECOG performance status of 0.
2. Case Presentation
Our patient is a 26-year-old male with no significant past
medical history. He presented to the hospital with a 3-month
history of shortness of breath, dry cough, and pleuritic chest
pain. His symptoms started gradually but started to worsen
about a week before presenting to the hospital. The shortness
of breathwasmainly exertional. Patientwas also experiencing
a dry cough related to this difficulty of breathing. He also
complained of pleuritic chest pain, bilaterally in both lower
chest fields, 5/10 in intensity, dull in nature without any
radiation. Aggravating factor included bouts of cough but
there were no specific relieving factors. The patient had also
noticed some unintentional weight loss but was unsure about
the amount of lost weight. Review of systems was negative for
fever or any exposure to sick contacts.There was no history of
night sweats. He did not have any risk factors for tuberculosis.
There was no history of any recent travel and the patient did
not complain of any leg swelling.
Physical examination showed a thin and lean male in
slight respiratory distress. Patient was found to be tachyp-
neic with a respiratory rate of 34 breaths per minute and
tachycardic with a heart rate of 118 beats per minute. He was
afebrile and normotensive. Auscultation of the lungs revealed
diffuse bilateral wheezing. Chest palpation was negative for
chest wall tenderness. Auscultation of the heart revealed
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Figure 1: Ultrasound of groin showing complex vascular mass.
normal S1 and S2 with no added sounds. Neurologically, the
patient was alert and oriented to time, place, and person.
He was able to follow commands with no focal neurological
deficits. Abdominal examination showed a soft, nontender
abdomenwith no organomegaly and normal bowel sounds. A
large, firm, nontendermass, with poorly definedmargins was
palpated in the right groin. It was not reducible and therewere
no signs of infection (no redness, tenderness, or warmth).
There was no change in the size or shape of themass when the
patient was asked to perform the valsalva maneuver. Accord-
ing to the patient, the mass had been slowly growing in his
groin for the past 2 years. Penile examinationwas negative for
any ulcers or discharge. Scrotal examination did not show any
apparent testicular masses.
The patient’s family history was negative for any signif-
icant problems. The patient did not smoke or drink alcohol
and had no risk factors for sexually transmitted diseases. He
was not taking any medications at the time of admission.
3. Investigations
Complete Blood Count (CBC) and basic metabolic panel
were normal.
Ultrasound of the pelvis and scrotum showed a 7.5 × 5.5 ×
5.9 cm complex vascular mass in the rightward mons pubis
with unremarkable sonographic appearance of the testicles
(Figure 1). MRI of the pelvis showed mass lesions involving
the right inguinal canal extending to the distal right iliac
chain likely consistentwith enlarged lymphnodes. Significant
effacement and mass effect was seen upon the right corpora
cavernosa of the penis without definite evidence of soft tissue
or osseous invasion (Figure 2). Significant narrowing and
effacement of the right external iliac veinwere seen at the level
of mass lesions.
Chest X-ray showed extensive parenchymal opacities
throughout both lungs with mediastinal fullness (Figure 3).
CT scan of the chest showed extensive mediastinal and
hilar lymphadenopathy with prominent interstitial changes
throughout both lungs and multiple diffuse pulmonary nod-
ules (Figure 4).
Ultrasound guided biopsy of the inguinal mass was car-
ried out and pathology results were consistent with desmo-
plastic small round cell tumour (DSRCT) (Figure 5). Immun-
ohistochemical staining showed desmin and cytokeratin
(CAM 5.2) positivity (Figure 6). CD56 immunostain and leu-
kocyte common antigen were negative. A fluorescent in situ
hybridization (FISH) assay was positive for EWSR1 break
apart (Figure 7). RT-PCR was negative for EWS-Fli1 and
EWS-ERG rearrangements, indicating absence of t(11;22)
and t(21;22), respectively, of Ewing’s sarcoma/PNET. Endo-
bronchial ultrasound (EBUS) guided biopsies of the lymph
nodes and pulmonarymasseswere performed.Thepathology
was consistent with desmoplastic small round cell tumor.
4. Treatment
The patient’s hospital course was complicated by respiratory
distress and hypoxia resulting in admission to the intensive
care unit where he was intubated for hypoxic respiratory
failure. The etiology was believed to be resorption atelectasis
secondary to the bronchial compression from metastatic
lesions and a pneumothorax from his malignancy. He had
a chest tube placed which successfully treated his pneu-
mothorax. While on the ventilator, he was initiated on and
completed cycle 1 of vincristine, cyclophosphamide, and
doxorubicin as a part of theMemorial SloanKetteringCancer
Center P6 chemotherapy protocol of VAC/IE (vincristine,
adriamycin, and cyclophosphamide alternating with ifos-
famide and etoposide). This resulted in significant regression
in his pulmonary tumour burden and subsequent extubation.
His course was also complicated by febrile neutropenia which
weremanaged with intravenous antibiotics, transfusions, and
growth factor support.Hewas eventually discharged from the
hospital in a stable condition after a 2-month-long inpatient
stay.
The patient continues to follow up with the oncology
clinic as an outpatient and gets electively admitted for his
chemotherapy.He is occupationally functional andmaintains
a good appetite. He maintains an ECOG performance status
of 0. He has completed 3 cycles of vincristine, cyclophos-
phamide, and doxorubicin followed by two cycles of ifos-
famide and etoposide. A restaging CT scan of the chest and
abdomen done after completion of radiation and cycle 4 of
VAC/IE has shown significant reduction in the size of his
groin mass and pulmonary metastases (Figures 3 and 4). He
has completed radiation therapy to the right groin mass for
a total of 37.5 Gray given as 2.5 Gray daily for a total of 15
fractions. He is currently scheduled to undergo autologous
stem cell transplant.
5. Discussion
Desmoplastic small round cell tumours (DSRCT) are a rare
group of sarcomas found in almost all age groups. Like all
other sarcomas, they are of mesenchymal origin. They occur
more commonly in adolescents and young adults. They were
first described in 1989 by Gerald and Rosai as small round
blue cell tumours with predilection for serosal surfaces and
occurring predominantly in youngCaucasianmaleswith pre-
dominantly intra-abdominal locations with focal rhabdoid
pattern with an intense desmoplastic reaction [1, 2]. Up till
2013, less than 200 cases had been reported in the world
literature [3].
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(a) (b)
Figure 2: MRI coronal (a) and transverse (b) section showing mass lesion in the right inguinal region with mass effect on the corpora
cavernosa of the penis.
(a) (b)
Figure 3: Chest X-ray with evidence of bilateral pulmonary opacities and hilar fullness on presentation (a) and after 4 cycles of VAC/IE
chemotherapy (b).
(a) (b)
Figure 4: CT chest with large masses bilaterally at level of bifurcation of trachea (a) and after 4 cycles of VAC/IE chemotherapy (b).
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(a) (b)
Figure 5: H&E stain (×200 on (a)) showing nests and sheets of small round blue cells infiltrating desmoplastic stroma. Tumour cells (×600
on (b)) with round to oval, hyperchromatic, mitotically active nuclei with scant cytoplasm.
(a) (b)
Figure 6: Immunohistochemical staining showing strong positivity for desmin (a) and focal positivity for cytokeratin (b).
Figure 7: FISH assay showing positivity for EWSR1 gene rearrange-
ment. Sixty five percent of the interphase cells showed separation of
EWSR1.
Histologically, the tumour consists of poorly differ-
entiated round cells with cytoplasmic densities and con-
nective tissue stroma. They typically show immunohis-
tochemical positivity for desmin, cytokeratin, vimentin,
and CAM5.2 [4]. The peculiar perinuclear dot-like stain-
ing pattern for vimentin and desmin is characteristic for
DSRCT. These tumours arise from a reciprocal transloca-
tion, t(11;22)(p13;q12), which results from fusion of Ewing’s
sarcoma (EWS) and Wilms’ tumour (WT1) genes [5–8].
Histopathology is not sufficient to diagnoseDRSCTas certain
other tumours such as primitive neuroectodermal tumour
canmimic DRSCT under themicroscope.Molecular analysis
is required for a final diagnosis [9].
The majority of the cases of DRSCT occur in the abdo-
men; however, many case reports have described this tumour
originating from different organs such as testis, extremities,
salivary glands, and brain [10–13]. Clinical presentation
depends on the primary location of the tumour as well as
disease stage. Diagnosis typically requires a tissue biopsy
with identification of histopathological features along with
immunohistochemistry and molecular testing. Fine-needle
aspiration has also been used for the diagnosis of DRSCT
[14]. As previously mentioned, hallmark feature in molecular
testing is the presence of WT1-EWS fusion; however, case
reports with atypical molecular features have also been
described [15].
Surgery, radiation therapy, and chemotherapy are modal-
ities that are utilized for the treatment ofDRSCTbut given the
rarity of the condition no large scale prospective trials exist
for head to head comparisons. Hyperthermic intraperitoneal
chemotherapy using Cisplatin has been utilized as a low
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morbidity treatment option for DSRCT patients [16–18].
The reported results have been variable with some studies
showing survival benefit when used instead of traditional
systemic chemotherapy [19–21]. Yttrium microspheres have
been used successfully to treat liver metastasis from DSRCT
[22]. For limited stage disease, complete surgical resection is
the treatment of choice. Based on the tumour size and grade,
neoadjuvant/adjuvant radiotherapy and chemotherapy can
be utilized.
The Memorial Sloan Kettering Cancer Center P6 pro-
tocol is one of the most studied and therefore commonly
used chemotherapy regimens for DSRCT. It consists of
seven cycles of chemotherapy. Cycles 1, 2, 3, and 6 include
high dose cyclophosphamide, doxorubicin, and vincristine
(VAC). Cycles 4, 5, and 7 consist of ifosfamide and etopo-
side (IE). Myeloablative chemotherapy with etoposide and
thiotepa, followed by allogeneic stem cell transplantation, has
been tried. Studies have shown that intense multimodality
approach is associated with better outcomes [23, 24]. Certain
investigational drugs, such as temsirolimus, an antiangio-
genic serine/threonine protein kinase inhibitor, are being
considered for these tumours, but the data on these is very
limited [25]. Another agent named pazopanib, a tyrosine
kinase inhibitor, is also under investigation for the treatment
of these tumours [26].
The 5-year survival rate of DRSCT is only approximately
15% [27]. The prognosis is generally poor as the majority of
the patients have metastatic disease at the time of presenta-
tion. The median survival ranges from 17 to 25 months [28].
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